Funding extension brings in $8M for antibody drug developer

04/1/2013 | MedCityNews.com

Theraclone Sciences secured an additional $8 million, bringing the total raised in its Series B funding round to $50 million. The Seattle biotech company is developing two antibodies for severe flu and cytomegalovirus infection.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT